Double-Blind , Placebo-Controlled Randomized Phase II Study of Hangeshashinto for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving Chemotherapy (HANGESHA-C Study).

ABSTRACT: Interventions: Oral administration of Hangeshashinto 7.5g/day t.i.d. after meals. Oral administration of Placebo 7.5g/day t.i.d. after meals. Primary outcome(s): Incidence of oral mucositis. grade>=2 Study Design: Parallel Randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2619737 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR